A slimmed down patent reform bill clamping down on demand letters appears the final hope for legislation to get passed in this Congress. But some patent reform supporters are worried a small bill would make it even harder to pass comprehensive reform in the future while others say a pause in efforts to get reform passed is no bad thing
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
Richard de Bodo, who had a lengthy career at international firms, shares how he will address client needs and praises the unique offerings of smaller firms
Despite being outspent by a wealthy opponent, a trial attorney at King & Spalding says ‘relentless pursuit of the truth’ helped his team secure a $420m damages award for mobile gaming client
190 drugs face loss of exclusivity between 2026 and 2030, with the list including Bristol Myers Squibb’s blood-thinning drug Eliquis and immunotherapy medication Opdivo